Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant
Christopher E. Dandoy(Cincinnati Children's Hospital Medical Center), Marcie Riches(Medical College of Wisconsin), Seth J. Rotz(Cleveland Clinic), Nosha Farhadfar(University of Florida Health), Rodrigo Martino(Universitat Autònoma de Barcelona), Saurabh Chhabra(Medical College of Wisconsin), Peiman Hematti(UW Health University Hospital), Shahrukh K. Hashmi(Mayo Clinic), Christopher C. Dvorak(University of California, San Francisco), Monica I. Ardura(Nationwide Children's Hospital), Caroline A. Lindemans(University Medical Center Utrecht), Roomi Nusrat(Rutgers, The State University of New Jersey), Krishna V. Komanduri(University of Miami), Taiga Nishihori(Moffitt Cancer Center), Anthony D. Sung(Duke University), Richard F. Olsson(AstraZeneca (Netherlands)), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Valerie I. Brown(BC Children's Hospital), Min Chen(Medical College of Wisconsin), Soyoung Kim(Medical College of Wisconsin), Miguel Ángel Díaz(Hospital Infantil Universitario Niño Jesús), Siddartha Ganguly(University of Kansas), Aron Flagg(Yale New Haven Hospital), Gregory A. Hale(Johns Hopkins University), Kwang Woo Ahn(Medical College of Wisconsin)
Cited by 70
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k